The global pharma ADMET testing market is expected to grow from US$ 6,783.06 million in 2021 to US$ 13,578.62 million by 2028; it is estimated to grow at a CAGR of 10.5% from 2022 to 2028.
The report highlights the key factors driving the market and prominent players with their developments. The growth of the global pharma ADMET testing market is majorly driven by the high rate of late-stage drug failure and increasing approvals and launches of products. Additionally, the rise of new and emerging technologies would emerge as a significant trend in the market during the forecast period. However, the high cost of ADMET testing studies hampers the market growth.
The COVID-19 pandemic positively impacted the pharma ADMET testing market due to the increased research activities in pharmaceutical industry across the world. During the pandemic, the demand for in vitro toxicology research increased to study several drugs and vaccines. Additionally, the increased number of researches led to high utilization of technology instead of human resource to prevent the spread of novel coronavirus. Thus, the technology segment grew at an exponential level. Moreover, the government of developing countries organized programs and open challenge events for researchers to come up with innovative drugs for COVID-19. Such events increased the overall research numbers due to the rise in government funding. With the use of advanced technologies, including AI and big data, the ADMET testing became easier as the data from the testing can be easily analyzed and stored using these technologies. For instance, a UK-based pharma company named Exscientia uses AI for drug discovery and development. Thus, the above-mentioned factors indicate the positive impact of COVID-19 pandemic on the pharma ADMET testing market.
Based on technology, the global pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment holds the largest share of the market in 2021. However, the high throughput segment is anticipated to register the highest CAGR of 10.9% during the forecast period. In the cell culture technique, cells are grown under controlled conditions to accurately depict and simulate the environment and perform ADMET testing at a cellular level. The technique is used to evaluate the cytotoxicity and permeability of drug molecules during the drug development process. The increasing use of cell culture technique is attributed to visual results at a cellular level, their ability to test with the smallest sample volumes, increased output in less time, and support from regulatory bodies to use cell cultures during the development process. Additionally, many studies have been conducted to study the ADMET profile of drug using the cell culture technique. A research article published in Frontiers Media in 2021 entitled “A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues” concluded that researchers developed a versatile microfluidic tissue-culturing platform for exposure of T47-D breast cancer spheroids to realistic pharmacokinetic drug concentration profiles BYL719 (anticancer compound). The cell culture model offers great flexibility and provides a versatile tool for in-depth preclinical evaluation of drug efficacy. Furthermore, key players operating in the pharma ADMET testing market are preferring to use 3D cell cultures than 2D, as 3D cell cultures allow researchers to make better-informed predictions. Sigma Aldrich and Creative Bioarray are among the major players possessing extensive experience in developing highly functional 3D cell culture models that exhibit physiological relevance.
CMIC HOLDINGS Co., LTD; Charles River Laboratories; WuXi AppTec; Promega Corporation; MERCK KGaA; Agilent Technologies, Inc.; Biovia (Dassault Systèmes); Cyprotex Limited; Bio-Rad Laboratories, Inc.; and IQVIA Inc. are among the leading companies in the pharma ADMET testing market.
Pharma ADMET Testing Market, by Region, 2021 (%)
Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)
Pharma ADMET Testing Market Global Analysis & Forecast 2028
Download Free Sample
The pharma ADMET testing market is segmented on the basis of testing type, technology, application, and geography. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. Based on application, the global pharma ADMET testing market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com